Should I Buy GlaxoSmithKline Plc?

Harvey Jones wonders whether to stock up on GlaxoSmithKline plc (LON: GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m shopping for shares right now, should I pop GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) into my basket?

Cold comforts

When stock markets caught a cold in May, I suggested GlaxoSmithKline would be the perfect pick-me-up for your portfolio. I had faith in Glaxo, but now it stands accused of bribing Chinese doctors and officials to use its medicines and has just posted a double-digit drop in operating profits. Should I still buy it?

If Glaxo is a great British company, it may be time for some national introspection. The pharmaceutical giant was already under investigation by the OFT for allegedly abusing its dominant market position over antidepressant treatment Seroxat, a charge Glaxo denies, when the China crisis blew up. Several senior executives have been arrested, without formal charges. The aggression of the Chinese authorities has shocked everybody. Chief executive Sir Andrew Witty’s decision to delegate the problem to senior manager Abbas Hussain has surprised many, who worry that he has failed to grasp the scale of the reputational threat.

The drugs do work

Combined with an underwhelming set of Q2 results, Glaxo doesn’t look so invigorating right now. Group turnover did increase by 2% at constant exchange rates, but operating profits fell 13%. Europe is a worry, as austerity-stricken governments look to cut healthcare spending and find cheap generic alternatives. Generic competition also hit sales in Japan. So is this the time to wean your portfolio off Glaxo?

You know the answer to that one. Glaxo remains a great core holding. Its current yield of 4.4% zaps the FTSE 100 average of 3.48%. Management hiked the Q2 dividend by 6% to 18p, and is targeting total share repurchases of between £1bn and £2bn this year, which should support the price. It is also cutting costs and dropping its non-core holdings, and there is talk of AG Barr lining up a £1 billion bid for its consumer brands Lucozade and Ribena. Best of all, Glaxo looks like it is building up a healthy drugs pipeline, which should drive future sales and profits.

Just the Glax, man

Glaxo’s share price is up 44% over three years (against 24% for the FTSE), 23% over two years (against 11%) and 17% over the past 12 months (against 18%). So investors have enjoyed steady, index-beating growth, as well as that yield. This kind of performance doesn’t come cheap, and Glaxo is trading at 15 times earnings, against 13.31 for the index as a whole. Operating margins of 20% and ROCE of 60% suggest a company in rude health. As does forecast earnings per share (EPS) growth of 3% this year and 9% in 2014. China is only a small part of the Glaxo operation, around 4%, but I suspect it could still do a disproportionate amount of damage. If that throws up a buying opportunity, take it. You won’t get many with a company like this.

There are plenty more great opportunities in the FTSE 100. If you want to know what they are, then download our free, in-depth report, Eight Top Blue Chips Held By Britain’s Super Investor. This report by Motley Fool analysts is completely free and shows where dividend maestro Neil Woodford believes the best high-yield stocks are to be found today. Availability of this report is strictly limited, so please download it now.

> Harvey owns shares in Glaxo.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Investing Articles

2 mouthwatering FTSE growth stocks I’d buy and hold for 10 years

Growth stocks purchased today could be the gateway to many years of capital growth and returns. Here are two picks…

Read more »

Investing Articles

Can the IAG share price really be as dirt cheap as it looks?

While most shares have recovered since the Covid days, the IAG share price is staying stuck to rock bottom. Surely…

Read more »

Investing Articles

BAE Systems shares are flying! Have I missed the boat?

Sumayya Mansoor looks into whether or not BAE Systems shares are still a good buy for her portfolio after the…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

1 heavyweight FTSE 100 share I’d buy as London retakes its crown

Some Footsie firms are extremely large, but that doesn't mean they couldn't get even bigger. Here's one such FTSE 100…

Read more »

Investing Articles

I’d buy 5,127 National Grid shares to generate £250 of monthly passive income

With a dividend yield of 6.5%, Muhammad Cheema takes a look at how National Grid shares can generate a healthy…

Read more »

Investing Articles

The FTSE 100’s newest member looks like a no-brainer to me!

This Fool explains why she sees the newest member of the FTSE 100 as a great opportunity after its recent…

Read more »

Investing Articles

Empty Stocks and Shares ISA? Here’s how I’d start earning a second income from scratch

Like the thought of earning extra cash tax free? Our writer explains what he'd do to begin earning passive income…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

No savings at 25? I’d start by investing £3k in these 3 red-hot FTSE 100 shares

Harvey Jones thinks these three FTSE 100 stocks would be a great way to kickstart a portfolio of UK shares.…

Read more »